

**RENEO PHARMACEUTICALS, INC.**  
18575 Jamboree Road, Suite 275-S  
Irvine, California 92612

May 5, 2022

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attn: Michael Davis

**Re: Reneo Pharmaceuticals, Inc.  
Registration Statement on Form S-3 (File No. 333-264616)  
Request for Acceleration of Effective Date**

Dear Mr. Davis:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Reneo Pharmaceuticals, Inc. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the "Registration Statement") and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on May 9, 2022, or as soon thereafter as possible, or at such other time as the Company or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Company hereby authorizes each of Jason Kent and Wade Andrews of Cooley LLP to make such a request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Jason Kent of Cooley LLP at (212) 479-6044, or in his absence, Wade Andrews of Cooley LLP at (858) 550-6042.

Very truly yours,

Reneo Pharmaceuticals, Inc.

/s/ Gregory J. Flesher

By: Gregory J. Flesher

Title: President and Chief Executive Officer